Alzheimer's & Cognition
From the Journals
Idalopirdine falls short in three phase 3 Alzheimer’s trials
Simultaneously, Axovant Life Sciences pulls plug on intepirdine, another 5-HT6 receptor drug, after failures in both AD and Lewy body dementia.
Conference Coverage
Cars that recognize hypoglycemia? Maybe soon
SAN DIEGO – An automobile that watches you.
Conference Coverage
Tau imaging predicts looming cognitive decline in cognitively normal elderly
BOSTON – Temporal lobe tau accumulation in cognitively normal older adults may be a good way of tracking Alzheimer’s disease progression.
Conference Coverage
Head injury linked to amyloid deposition decades later
SAN DIEGO – Increased amyloid deposition found in the frontal cortex but not other areas associated with Alzheimer’s disease.
From the Journals
Up to 47 million Americans may have “preclinical” Alzheimer’s disease, study estimates
A primary prevention treatment that cut the risk of amyloidosis would sharply decrease this number, the modeling study found.
Conference Coverage
Retinal changes may reflect brain changes in preclinical Alzheimer’s
BOSTON – The retina could be “a window that could let us see what’s happening in the brain in early Alzheimer’s disease.”
Conference Coverage
Walking has beneficial cognitive effects in amyloid-positive older adults
BOSTON – Over 4 years, those who walked the most experienced the least cognitive decline.
Conference Coverage
Intepirdine flops in phase 3 study of mild to moderate Alzheimer’s patients
BOSTON – But investigation continues in a phase 3 placebo-controlled study in patients with Lewy body dementia.
Conference Coverage
Development of a sigma 1 receptor agonist for Alzheimer’s proceeds based on 2-year phase 2 data
BOSTON – Some patients taking ANAVEX 2-73 improved cognition and function over 109 weeks.
Conference Coverage
Long-term cholinesterase inhibition may slow cognitive decline – and more
BOSTON – New data suggest the drugs also reduce risk of heart attack, stroke, and all-cause mortality.
Conference Coverage
Pimavanserin found modestly effective in phase 2 Alzheimer’s psychosis study
BOSTON – The drug’s small improvement in psychotic symptoms may take weeks to appear, but its effect seemed to spare cognition.